- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01410565
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1R3S3
- Centre Hospitalier Universitaire de Quebec
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8V3N1
- G. Steinhoff Clinical Research Pacific Urologic Research
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Queen Elizabeth II Health Science Center
-
-
Ontario
-
Barrie, Ontario, Canada, L4M7G1
- The Male/Female Health and Research Centre - Royal Court Medical Centre
-
Brantford, Ontario, Canada, N3R4N3
- Brantford Urology Research
-
Burlington, Ontario, Canada, L7N3V2
- G. Kenneth Jansz Medicine Professional Corporation
-
Burlington, Ontario, Canada, L7S1V2
- Urology Resource Centre
-
Kingston, Ontario, Canada, K7L3J7
- Kingston General Hospital / Queen's University
-
Kitchener, Ontario, Canada, N2N2B9
- Urology Associates, Urologic Medical Research
-
Newmarket, Ontario, Canada, L3X1W1
- Mor Urology, Inc.
-
North Bay, Ontario, Canada, P1B7K8
- Office of Bernard Goldfarb
-
North York, Ontario, Canada, M2J1V1
- Stanley Flax Medical Professional Corporation
-
Oakville, Ontario, Canada, L6H3P1
- The Fe/Male Health Centre
-
Oshawa, Ontario, Canada, L1H7K4
- Urotec
-
Scarborough, Ontario, Canada, M1S4V5
- Urology/Male Infertility
-
Toronto, Ontario, Canada, M4N3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5G2M9
- University Health Network Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3G1A4
- Centre universitaire de sante McGill
-
Sherbrooke, Quebec, Canada, J1H5N4
- Centre hospitalier universitaire de Sherbrooke
-
-
-
-
Arizona
-
Glendale, Arizona, United States, 85308
- Valley Urologic Associates
-
Phoenix, Arizona, United States, 85032
- Precision Trials, LLC
-
-
California
-
Laguna Woods, California, United States, 92653
- South Orange County Medical Research Center
-
-
Colorado
-
Denver, Colorado, United States, 80211
- The Urology Center of Colorado
-
-
Connecticut
-
Middlebury, Connecticut, United States, 06762
- Connecticut Clinical Research Center
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Urology Enterprises
-
-
Idaho
-
Coeur d'Alene, Idaho, United States, 83814
- North Idaho Urology
-
Meridian, Idaho, United States, 83642
- Idaho Urologic Institute, P.A.
-
-
Indiana
-
Ft. Wayne, Indiana, United States, 46825
- Northeast Indiana Research, LLC
-
Jeffersonville, Indiana, United States, 47130
- First Urology, PSC
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71106
- Regional Urology, LLC
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Anne Arundel Urology
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Spectrum Health Medical Group
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55418
- University of Minnesota
-
-
Montana
-
Missoula, Montana, United States, 59802
- Five Valleys Urology
-
-
New Jersey
-
Voorhees, New Jersey, United States, 08043
- Delaware Valley Urology, LLC - Voorhees
-
Westampton, New Jersey, United States, 08060
- Delaware Valley Urology, LLC-Westampton
-
-
New York
-
New York, New York, United States, 10016
- University Urology Associates
-
Rochester, New York, United States, 14618
- Urology Associates of Rochester, LLC
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- TriState Urologic Services PSC, Inc.
-
-
Pennsylvania
-
Bala Cynwyd, Pennsylvania, United States, 19004
- Urologic Consultants of Southeastern Pennsylvania, LLP
-
Bryn Mawr, Pennsylvania, United States, 19010
- Urology Health Specialists
-
Lancaster, Pennsylvania, United States, 17604
- Urological Associates of Lancaster
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Carolina Urologic Research Center
-
-
Texas
-
McAllen, Texas, United States, 78503
- Urology Associates of South Texas
-
-
Virginia
-
Virginia Beach, Virginia, United States, 23454
- Urology of Virginia, PC
-
Virginia Beach, Virginia, United States, 23462
- Urology of Virginia, PLLC
-
-
Washington
-
Mountlake Terrace, Washington, United States, 98043
- Integrity Medical Research, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Open Phase Inclusion Criteria:
- Has the patient given written informed consent and is the patient willing and able to abide by the protocol?
- Is the patient 18 years old or above?
- If the patient is a female of childbearing potential, is she using an acceptable/effective method of contraception?
- Does the female patient of childbearing potential have a negative serum pregnancy test at screening?
Does the patient with clinically apparent primary or recurrent low grade Ta NMIBC have :
- multiple tumors (2-7)
- No single Tumor > 3 cm
- No history / evidence of Tis
Or does the patient with clinically apparent primary or recurrent high grade Ta NMIBC have:
- A single tumor that is ≤ 3 cm
- No history / evidence of Tis
- Is the patient able to retain bladder instillations for a minimum of 60 minutes?
- Did the patient have upper urinary tract evaluation to exclude urothelial carcinoma, hydronephrosis or renal cell carcinoma or other renal cancers in the 6 months prior to study screening?
- Is patient's urethra (including prostatic urethra in men) endoscopically free of any visible TCC?
- For patients with recurrent tumor, did the patient have at least a 6-month cystoscopically-confirmed tumor-free interval between the last tumor recurrence and the time of screening?
- Has the male patient with a prostate specific antigen (PSA) between 4 and 10 ng/mL had a diagnostic evaluation that reasonably excludes the diagnosis of prostate cancer in the opinion of the Investigator?
Double-Blind Phase Inclusion Criteria:
- Was all visible tumor resected at the initial TURBT?
Does Central Pathology review of the patient's bladder tumor confirm:
- Low grade Ta disease for multiple tumors (2 - 7) or
- High Grade Ta disease for single tumor
- No microscopic evidence of lymphovascular invasion and/or evidence of tumor thromboemboli
Exclusion Criteria:
Open Phase Exclusion Criteria:
- Has the patient received any previous pelvic radiotherapy (includes external beam and/or brachytherapy)?
- Has the patient ever received apaziquone?
- Has the patient received an induction course (completed 5 of 6 scheduled weekly instillations) of intravesical BCG (± interferon) with the last dose given less than 12 months ago?
- Has the patient had any prior intravesical chemotherapy, exclusive of single-dose adjuvant intravesical chemotherapy immediately post-TURBT?
- Does the patient have a history of urinary retention or a post void residual ≥ 250 cc by bladder scan or ultrasound (post void residual test may be repeated up to 3 times)?
- Does the patient have or has the patient had any bladder tumor with histology other than transitional cell carcinoma?
- Does the patient have or has the patient had micro-papillary transitional cell carcinoma?
- If the patient has recurrent papillary disease of the bladder, has the pathology been anything other than pTa in the past?
- Does the patient have an active urinary tract infection confirmed by culture or a documented history of recurrent UTI (≥ 6 for females and ≥2 for males per year) in the prior 2 years?
- Does the patient have a bleeding disorder or a screening platelet count < 50 x 109/L?
- Does the patient have a screening hemoglobin < 10 mg/dL?
- Does the male patient have a serum PSA > 10 ng/mL?
- Does the patient have a history of Acquired Immunodeficiency Syndrome or HIV positive?
- Does the patient have a condition or a concurrent severe and/or uncontrolled medical or psychiatric disease (e.g., uncontrolled diabetes, decompensated congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, or an active uncontrolled infection), which could compromise participation, compliance with scheduled visits and/or completion of the study?
- Has the patient participated in an investigational protocol within the past 90 days?
- Is the patient pregnant or breast feeding?
- Does the patient have a life expectancy of <3 years?
Has the patient had any other malignancy or received therapy for any malignancy in the last five years except
- non-melanoma skin tumors
- stage 0 (in situ) cervical carcinoma
- undetectable PSA for ≥1 year following definitive therapy for localized prostate cancer?
- Does the patient have documented vesicoureteral reflux or an indwelling ureteral stent?
- Does the patient have tumor in a bladder diverticulum?
- Does the patient have a known allergy to red color food dye?
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo for Double Blind Phase
|
Active Comparator: Apaziquone
|
Apaziquone 4 mg in 40 mL diluent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Recurrence
Time Frame: Recurrence of cancer in the bladder during 24 months of follow-up
|
Time to recurrence is the time from randomization to the date of first histologically confirmed recurrence of bladder cancer (for eligible patients with Low- intermediate risk NMIBC, who had undergone TURBT followed by, a single instillation of apaziquone immediately post TURBT and multiple instillations of apaziquone or placebo).
|
Recurrence of cancer in the bladder during 24 months of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence Rate at 24 Months
Time Frame: 24 months
|
Measurement the number of participants with the recurrence at 24 months.
|
24 months
|
Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: 24 Months from Randomization
|
TEAEs will be mainly characterized by the number of treatment emergent adverse events and treatment related AEs that occur or worsen after the first dose of study treatment.
|
24 Months from Randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Show-Li Sun, MD, Spectrum Pharmaceuticals, Inc
Publications and helpful links
General Publications
- Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S, Bartoletti R. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol. 2008 Jul;180(1):110-5. doi: 10.1016/j.juro.2008.03.038. Epub 2008 May 15.
- Schellens JH, Planting AS, van Acker BA, Loos WJ, de Boer-Dennert M, van der Burg ME, Koier I, Krediet RT, Stoter G, Verweij J. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst. 1994 Jun 15;86(12):906-12. doi: 10.1093/jnci/86.12.906.
- Stenzl A, Hennenlotter J, Schilling D. Can we still afford bladder cancer? Curr Opin Urol. 2008 Sep;18(5):488-92. doi: 10.1097/MOU.0b013e32830b8925.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPI-1011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
Clinical Trials on Apaziquone
-
Handok Inc.CompletedBladder CancerKorea, Republic of
-
Nippon Kayaku Co., Ltd.Handok Inc.TerminatedBladder CancerJapan, Korea, Republic of
-
Spectrum Pharmaceuticals, IncCompleted
-
Spectrum Pharmaceuticals, IncCompleted
-
Spectrum Pharmaceuticals, IncTerminated
-
Spectrum Pharmaceuticals, IncAllerganTerminatedBladder CancerUnited States, Poland, Czechia, Slovakia
-
Spectrum Pharmaceuticals, IncCompletedBladder CancerCanada, United States, Poland
-
Spectrum Pharmaceuticals, IncTerminated